Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 204

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

“Sero-Switch” Adenovirus-Mediated In Vivo Gene Transfer: Circumvention of Anti-Adenovirus Humoral Immune Defenses Against Repeat Adenovirus Vector Administration by Changing the Adenovirus Serotype

Mastrangeli, Andrea, Harvey, Ben-Gary, Yao, Jeffrey, Wolff, Gerhard, Kovesdi, Imre, Crystal, Ronald G., Falck-Pedersen, Erik · 1996 · Human Gene Therapy

Abstract

Recombinant, replication-deficient adenovirus (Ad) vectors have been successfully used to transfer and express the normal human cystic fibrosis transmembrane conductance regulator (CFTR) cDNA in vivo in the respiratory epithelium of experimental animals and humans with cystic fibrosis (CF). Since Ad-directed gene expression wanes over time, repeat administration is necessary to achieve an effective treatment for CF. A major hurdle to such a strategy is the possibility that anti-Ad humoral immunity may prevent gene expression in individuals with pre-existing anti-Ad immunity or following repeat administration. One strategy to circumvent such a problem would be alternating the use of Ad vectors belonging to different subgroups. Neutralizing antibodies developed with the administration of one Ad serotype do not cross-react with an Ad belonging to a second serotype in a manner that blocks infection and gene expression. To test this hypothesis, an immunizing dose of wild-type Ad5 (subgroup C), Ad4 (subgroup E), or Ad30 (subgroup D) was administered intratracheally to experimental animals, followed by an intratracheal administration of a replication-deficient subgroup C-derived vector coding for marker genes (chloramphenicol acetyl transferase or β-galactosidase) or for the normal human CFTR cDNA. As expected, studies with vectors coding for marker genes or for CFTR cDNA demonstrated that airway administration of a vector does not yield efficient gene transfer, if there has been prior recent airway administration of the same Ad subgroup. In contrast, effective expression from the second administration can be achieved with an adenovirus vector belonging to a subgroup different from the first adenovirus administered. These data support the paradigm of alternating Ad vectors derived from different subgroups as strategy to circumvent anti-Ad humoral immunity, thus permitting the use of Ad vectors as a means to treat the respiratory manifestations of CF. The respiratory manifestations of cystic fibrosis (CF) are potentially amenable to treatment by somatic gene therapy, using replication-deficient, recombinant adenovirus (Ad) vectors to transfer and express the cystic fibrosis transmembrane conductance regulator (CFTR) cDNA in vivo to the respiratory epithelium of CF individuals. Potential limitations to the use of Ad vectors to treat the respiratory manifestations of CF are the lack of integration of the vector DNA in the host cell genome, and the natural turnover of the airway epithelium with the consequent need for repetitive administration to achieve chronic expression of the normal CFTR gene. Ad are antigenic and anti-Ad neutralizing immunity may prevent successful repetitive administration of the Ad vector. The present study demonstrates that despite the presence of anti-Ad neutralizing antibodies it may be feasible to achieve successful repeated administration by alternating adenoviruses belonging to different subgroups.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/hum.1996.7.1-79

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 204

Metadata

Authors
Mastrangeli, A., Harvey, B.-G., Yao, J., Wolff, G., Kovesdi, I., Crystal, R. G., & Falck-Pedersen, E.
Venue
Human Gene Therapy
Published
1996-01
Volume
7
Issue
1
Pages
79-87
ISSN
  • 1043-0342 (ISSN-L)
  • 1557-7422
OpenAlex
W1972244141
Cited by
204
References
2
FWCI
8.22
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.